Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

IOL Power Formula Prediction Accuracy at the Extremes of Axial Length: A Prospective Outcome Verification Study (FORMULEX-OV)

21. července 2026 aktualizováno: Pia Veronika Vécsei-Marlovits, Vienna Hospital Association

Clinical Outcomes of Formula-dependent IOL Power Selection at the Extremes of Axial Length: a Cross-sectional Outcome Verification of Seven ESCRS-hosted Formulas and the Ladas Super Formula 2.0 in Short (<22.0 mm) and Long (>26.0 mm) Eyes Using Refractive, Biometric, and Tomographic Assessment

This single-center, prospective, cross-sectional study evaluates how accurately eight modern intraocular lens (IOL) power calculation formulas predicted the postoperative refractive result in eyes with extreme axial length after cataract surgery. Patients previously operated at the study center who had a very short (axial length < 22.0 mm) or very long (> 26.0 mm) eye and received a spherical monofocal IOL are invited to a single, non-invasive outcome visit. At this visit, standardized manifest refraction, optical biometry, corneal tomography, slit-lamp examination and, in long eyes, macular OCT are performed. The measured postoperative spherical equivalent is compared with the residual refraction that each of the eight formulas had predicted for the actually implanted IOL power, separately in short and long eyes. The study aims to identify which formula predicts the postoperative outcome most accurately at the extremes of axial length, where formula choice is most consequential and least well studied.

Přehled studie

Postavení

Zatím nenabíráme

Detailní popis

Modern IOL power formulas achieve high refractive predictability in average-length eyes but deteriorate at the extremes of axial length, where effective lens position modelling diverges most between formulas. A preceding retrospective study at this center quantified the formula-dependent variability of IOL power recommendations at the axial length extremes using fully standardized biometric inputs; however, planning discrepancy alone does not indicate which formula's recommendation yields the better clinical outcome. This prospective outcome verification study closes that gap by linking a standardized postoperative assessment to the pre-existing, pseudonymized preoperative planning dataset.

Design: single-center, prospective, cross-sectional, observational (paired within-eye) study. From the retrospective source cohort (approximately 927 short and 769 long eyes; approximately 1,000-1,200 patients; index surgeries January 2022-December 2025), a stratified random sample of 200 patients is drawn (110 short stratum, 90 long stratum; 55:45 ratio) and invited to a single outcome visit. Each eligible eye contributes up to eight paired, formula-specific prediction errors that differ only by the calculation formula, while the postoperative reference (manifest refraction) and all preoperative inputs are held constant. Eyes are stratified a priori into a short (AL < 22.0 mm) and a long (AL > 26.0 mm) stratum and analyzed separately.

Formulas evaluated: Barrett Universal II, Cooke K6, EVO 2.0, Hill-RBF 3.0, Hoffer QST, Kane and PEARL-DGS (via the ESCRS IOL calculator), and the stand-alone Ladas Super Formula 2.0.

Outcome visit (single visit, all non-invasive standard ophthalmic techniques, no study-mandated therapy, medication or surgery): uncorrected and best-corrected distance visual acuity, IOLMaster 700 optical biometry, CASIA2 and Pentacam AXL corneal tomography, autorefraction and standardized subjective manifest refraction (primary outcome measure), slit-lamp examination with posterior capsule opacification grading, and macular OCT (obligatory in the long stratum, recommended in the short stratum).

Primary analysis: for each formula, the spherical equivalent prediction error (SE-PE = measured postoperative spherical equivalent minus the residual spherical equivalent predicted for the actually implanted IOL power step) is computed and the absolute error (|SE-PE|) compared globally across the eight formulas using the Friedman test, with post-hoc pairwise Wilcoxon signed-rank tests (Holm-corrected, 28 formula pairs), separately in each axial length stratum. The primary accuracy metric per formula is the median absolute prediction error.

All data are processed in pseudonymized form and linked via a study ID and laterality, in accordance with the Declaration of Helsinki (2024), ICH-GCP, and the GDPR. The study is reported per STROBE and is registered on ClinicalTrials.gov prior to the start of recruitment.

Typ studie

Pozorovací

Zápis (Odhadovaný)

200

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • State of Vienna
      • Vienna, State of Vienna, Rakousko, 1130
        • Klinik Hietzing, Augenabteilung
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dítě
  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

Adults previously enrolled in the retrospective IOL power formula comparison study at the extremes of axial length at the study center, who underwent cataract surgery with a spherical (non-toric) monofocal IOL (HOYA Vivinex XY1, HOYA Vivinex Impress XY1-EM, or Johnson & Johnson Tecnis 1-Piece DIB00) between January 2022 and December 2025, and whose preoperative axial length was below 22.0 mm or above 26.0 mm. A stratified random sample of 200 patients (110 short-eye, 90 long-eye) is drawn from this source cohort and invited to a single outcome visit.

Popis

Inclusion Criteria:

  • - Participation in the retrospective IOL power formula comparison study at the extremes of axial length (pseudonymized study ID assigned; complete preoperative biometry and archived formula outputs for all eight formula pathways)
  • Cataract surgery with a spherical (non-toric) IOL of one of the three reference models (HOYA Vivinex XY1, HOYA Vivinex Impress XY1-EM, or Johnson & Johnson Tecnis 1-Piece DIB00) at the study center between January 2022 and December 2025
  • Preoperative axial length below 22.0 mm (short stratum) or above 26.0 mm (long stratum), measured on IOLMaster 700
  • Documented implanted IOL model and power available from the operative record
  • At least 3 months since cataract surgery at the time of the outcome visit
  • Written informed consent for the outcome visit, including linkage of newly acquired postoperative data with the previously collected, pseudonymized preoperative planning data

Exclusion Criteria:

  • - Interval ocular surgery on the study eye since the original cataract surgery that may affect refraction or IOL position (e.g., corneal refractive surgery, IOL exchange or repositioning, secondary IOL implantation, or any intraocular surgery). Uncomplicated YAG laser capsulotomy without IOL repositioning is not an exclusion criterion
  • Implanted IOL not matching one of the three reference platforms (e.g., toric, multifocal or EDOF IOL, a different monofocal platform, or a sulcus-fixated IOL)
  • Toric IOL implantation
  • Acute ocular pathology preventing reliable refraction or biometric measurement
  • Cognitive or physical limitations precluding standardized subjective manifest refraction
  • Documented intraoperative complication with confirmed or suspected IOL malpositioning (e.g., posterior capsule rupture with vitreous loss, zonular dialysis requiring a capsular tension ring, sulcus placement)
  • Withdrawal of informed consent

Note: macular pathology is not an exclusion criterion; macular status is documented on OCT and analyzed as a covariate.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
Short axial length stratum (AL < 22.0 mm)
Pseudophakic eyes with a preoperative axial length below 22.0 mm that received a spherical monofocal IOL. These eyes undergo the standardized postoperative outcome visit; the measured spherical equivalent is compared with each formula's prediction for the implanted IOL power.
A single, non-invasive multimodal assessment: uncorrected and best-corrected distance visual acuity, IOLMaster 700 optical biometry, CASIA2 and Pentacam AXL corneal tomography, autorefraction and subjective manifest refraction, slit-lamp examination with posterior capsule opacification grading, and macular OCT. No therapeutic intervention, medication or surgery is performed.
Long axial length stratum (AL > 26.0 mm)
Pseudophakic eyes with a preoperative axial length above 26.0 mm that received a spherical monofocal IOL. These eyes undergo the standardized postoperative outcome visit (including obligatory macular OCT); the measured spherical equivalent is compared with each formula's prediction for the implanted IOL power.
A single, non-invasive multimodal assessment: uncorrected and best-corrected distance visual acuity, IOLMaster 700 optical biometry, CASIA2 and Pentacam AXL corneal tomography, autorefraction and subjective manifest refraction, slit-lamp examination with posterior capsule opacification grading, and macular OCT. No therapeutic intervention, medication or surgery is performed.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Spherical equivalent prediction error (SE-PE) across eight IOL power formulas, compared within each axial length stratum
Časové okno: Single study visit, at least 3 months after cataract surgery
For each eye, SE-PE is calculated as the measured postoperative spherical equivalent (standardized manifest refraction) minus the residual spherical equivalent predicted by each formula for the actually implanted IOL power step. The absolute prediction error (|SE-PE|) is compared globally across the eight formulas (Barrett Universal II, Cooke K6, EVO 2.0, Hill-RBF 3.0, Hoffer QST, Kane, PEARL-DGS, Ladas Super Formula 2.0) using the Friedman test, with post-hoc pairwise Wilcoxon signed-rank tests (Holm-corrected, 28 formula pairs), performed separately in the short (AL < 22.0 mm) and long (AL > 26.0 mm) strata. The primary accuracy metric per formula is the median absolute prediction error (MedAE).
Single study visit, at least 3 months after cataract surgery

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. srpna 2026

Primární dokončení (Odhadovaný)

1. června 2027

Dokončení studie (Odhadovaný)

1. července 2027

Termíny zápisu do studia

První předloženo

14. července 2026

První předloženo, které splnilo kritéria kontroly kvality

21. července 2026

První zveřejněno (Aktuální)

24. července 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

24. července 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

21. července 2026

Naposledy ověřeno

1. července 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • MA_15_EK_26_128_VK

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit